This nationwide, claims-based study offers a comprehensive characterization of real-world pharmacological management of overactive bladder (OAB) in Japan, with particular emphasis on older adults. By analyzing initial drug selection, treatment persistence, and the use of guideline-recommended diagnostic tests across medical specialties and facility types, the authors address clinically pertinent questions that have been insufficiently examined in prior Japanese research. The predominance of elderly participants (median age, 80 years) and the assessment of urinalysis and postvoid residual (PVR) measurement constitute notable strengths of this study 1. A key consideration when conducting analyses based on Japanese medical billing data (claims-based) is that diagnostic information is primarily recorded for insurance reimbursement purposes. In practice, independently collecting datasets of this scale is extremely difficult, and utilizing a nationwide medical billing database is often the only realistic option. Nevertheless, when interpreting research papers, it is necessary to carefully consider the inherent advantages and limitations of medical billing data. The age distribution in this study—median age 80 years—indicates that a nontrivial proportion of participants with dementia would be expected. It is therefore noteworthy that dementia was present in 11.7% of anticholinergic users in the dataset. Although numerous prior reports have suggested an association between anticholinergic use and cognitive impairment 2, 3, the present study does not establish causality, and this distinction must be emphasized. Moreover, because patients may receive prescriptions for drugs with anticholinergic activity from specialties other than urology, future investigations should review all prescriptions and assess the overall anticholinergic burden. In the current analysis, men comprised 43.7% of the cohort, and β3-adrenergic receptor agonists were prescribed more frequently to men with benign prostatic hyperplasia (BPH). The authors interpret this pattern as reflecting concerns about the risk of urinary retention due to bladder outlet obstruction from BPH and the perception that β3-agonists carry a lower risk of urinary retention than anticholinergics. However, in routine clinical practice, α1-blockers or phosphodiesterase-5 inhibitors are typically used as first-line therapy for patients with BPH, and β3-agonists or anticholinergics are considered only for residual overactive bladder symptoms. Thus, without careful ascertainment of concomitant medications, interpretation of the present findings is challenging. In any case, the ability to analyze data at this scale is a major strength of nationwide claims-based databases, and further study is warranted. The author takes full responsibility for this article. The author declares no conflicts of interest. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Takeya Kitta (Fri,) studied this question.